Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
KPTI's Cash to Debt is ranked higher than
88% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.03 vs. KPTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
KPTI' s 10-Year Cash to Debt Range
Min: N/A   Max: No Debt
Current: No Debt


Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6421
N/A
No Debt
Z-Score: 33.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -38721.49
KPTI's Operating margin (%) is ranked lower than
77% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. KPTI: -38721.49 )
Ranked among companies with meaningful Operating margin (%) only.
KPTI' s 10-Year Operating margin (%) Range
Min: -33120.52   Max: -2506.31
Current: -38721.49

-33120.52
-2506.31
Net-margin (%) -38662.28
KPTI's Net-margin (%) is ranked lower than
77% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.76 vs. KPTI: -38662.28 )
Ranked among companies with meaningful Net-margin (%) only.
KPTI' s 10-Year Net-margin (%) Range
Min: -33090.39   Max: -2505.99
Current: -38662.28

-33090.39
-2505.99
ROE (%) -44.71
KPTI's ROE (%) is ranked lower than
70% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.48 vs. KPTI: -44.71 )
Ranked among companies with meaningful ROE (%) only.
KPTI' s 10-Year ROE (%) Range
Min: -53.44   Max: -41.9
Current: -44.71

-53.44
-41.9
ROA (%) -42.61
KPTI's ROA (%) is ranked lower than
76% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. KPTI: -42.61 )
Ranked among companies with meaningful ROA (%) only.
KPTI' s 10-Year ROA (%) Range
Min: -372.3   Max: -40.03
Current: -42.61

-372.3
-40.03
ROC (Joel Greenblatt) (%) -4552.65
KPTI's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.04 vs. KPTI: -4552.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KPTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11975.31   Max: -5066.53
Current: -4552.65

-11975.31
-5066.53
» KPTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

KPTI Guru Trades in Q1 2014

Steven Cohen Sold Out
» More
Q2 2014

KPTI Guru Trades in Q2 2014

Paul Tudor Jones 15,000 sh (New)
Steven Cohen 8,000 sh (unchged)
» More
Q3 2014

KPTI Guru Trades in Q3 2014

Steven Cohen 39,400 sh (+392.50%)
Paul Tudor Jones Sold Out
» More
Q4 2014

KPTI Guru Trades in Q4 2014

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KPTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Karyopharm Therapeutics Inc.

Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Inc. and Nimble Storage Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Karopharm Therapeuticcs Inc, Methode Electronics Inc, Gilead Sciences Inc, and Nimble Storage Inc. Read more...

Ratios

vs
industry
vs
history
P/B 3.30
KPTI's P/B is ranked higher than
54% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. KPTI: 3.30 )
Ranked among companies with meaningful P/B only.
KPTI' s 10-Year P/B Range
Min: 3.25   Max: 10.64
Current: 3.3

3.25
10.64
P/S 15372.13
KPTI's P/S is ranked lower than
123% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. KPTI: 15372.13 )
Ranked among companies with meaningful P/S only.
KPTI' s 10-Year P/S Range
Min: 0   Max: 15372.1
Current: 15372.13

0
15372.1
Current Ratio 16.96
KPTI's Current Ratio is ranked higher than
96% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. KPTI: 16.96 )
Ranked among companies with meaningful Current Ratio only.
KPTI' s 10-Year Current Ratio Range
Min: 0.49   Max: 47.98
Current: 16.96

0.49
47.98
Quick Ratio 16.96
KPTI's Quick Ratio is ranked higher than
97% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. KPTI: 16.96 )
Ranked among companies with meaningful Quick Ratio only.
KPTI' s 10-Year Quick Ratio Range
Min: 0.49   Max: 47.98
Current: 16.96

0.49
47.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.20
KPTI's Price/Net Cash is ranked higher than
93% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. KPTI: 4.20 )
Ranked among companies with meaningful Price/Net Cash only.
KPTI' s 10-Year Price/Net Cash Range
Min: 4.47   Max: 10.95
Current: 4.2

4.47
10.95
Price/Net Current Asset Value 4.20
KPTI's Price/Net Current Asset Value is ranked higher than
91% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. KPTI: 4.20 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KPTI' s 10-Year Price/Net Current Asset Value Range
Min: 4.41   Max: 10.7
Current: 4.2

4.41
10.7
Price/Tangible Book 3.50
KPTI's Price/Tangible Book is ranked higher than
58% of the 824 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.50 vs. KPTI: 3.50 )
Ranked among companies with meaningful Price/Tangible Book only.
KPTI' s 10-Year Price/Tangible Book Range
Min: 4.4   Max: 10.51
Current: 3.5

4.4
10.51
Earnings Yield (Greenblatt) -12.30
KPTI's Earnings Yield (Greenblatt) is ranked lower than
80% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. KPTI: -12.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
KPTI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -15.3   Max: 0
Current: -12.3

-15.3
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:25K.Germany,
» More Articles for KPTI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Jul 06 2014 

More From Other Websites
Karyopharm Initiates STORM Clinical Trial of Oral Selinexor (KPT-330) in Multiple Myeloma May 28 2015
8:01 am Karyopharm Therapeutics announces initiation of clinical trial of oral Selinexor in multiple... May 28 2015
Karyopharm Initiates STORM Clinical Trial of Oral Selinexor (KPT-330) in Multiple Myeloma May 28 2015
Karyopharm to Present Clinical Data Update for Selinexor (KPT-330) in Solid Tumors May 27 2015
Karyopharm to Present Clinical Data Update for Selinexor (KPT-330) in Solid Tumors May 27 2015
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 26 2015
KARYOPHARM THERAPEUTICS INC. Financials May 22 2015
Karyopharm to Present Hematologic Cancer Data on Lead Drug Candidate Selinexor at European... May 21 2015
Karyopharm to Present Hematologic Cancer Data on Lead Drug Candidate Selinexor at European... May 21 2015
Karyopharm to Present Solid Tumor Data on Lead Drug Candidate Selinexor at 2015 American Society of... May 13 2015
Karyopharm to Present Solid Tumor Data on Lead Drug Candidate Selinexor at 2015 American Society of... May 13 2015
Leerink Is Changing Targets At These 7 Biotechs May 12 2015
Karyopharm Reports First Quarter 2015 Financial Results and Highlights Recent Progress May 11 2015
Karyopharm Therapeutics Inc Earnings Call scheduled for 8:30 am ET today May 11 2015
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 11 2015
Q1 2015 Karyopharm Therapeutics Inc Earnings Release - Before Market Open May 11 2015
Karyopharm Therapeutics posts 1Q loss May 11 2015
Karyopharm Therapeutics posts 1Q loss May 11 2015
Karyopharm Reports First Quarter 2015 Financial Results and Highlights Recent Progress May 11 2015
Karyopharm to Present at Bank of America Merrill Lynch 2015 Healthcare Conference May 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK